[1
]
Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA),
Avenida de Pio XII, 55, 31008 Pamplona, Spain; Navarra Institute for Health Research
(IDISNA), Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC),
Madrid, Spain.
[2
]
Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA),
Avenida de Pio XII, 55, 31008 Pamplona, Spain; Navarra Institute for Health Research
(IDISNA), Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC),
Madrid, Spain; Department of Immunology and Immunotherapy, Clínica Universidad de
Navarra, Pamplona, Spain.
[3
]
Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA),
Avenida de Pio XII, 55, 31008 Pamplona, Spain; Navarra Institute for Health Research
(IDISNA), Pamplona, Spain.
[4
]
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Vall
d'Hebron Institute of Oncology (V.H.I.O.), Barcelona, Spain.
[5
]
Program against Cancer Therapeutic Resistance (ProCURE), IDIBELL, Catalan Institute
of Oncology, L'hospitalet del Llobregat, Barcelona, Spain.
[6
]
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Program
against Cancer Therapeutic Resistance (ProCURE), IDIBELL, Catalan Institute of Oncology,
L'hospitalet del Llobregat, Barcelona, Spain; Department of Medical Oncology, IDIBELL,
Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain.
[7
]
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Department
of Pathology Hospital Universitari Arnau de Vilanova, University of Lleida, IRB-Lleida,
Lleida, Spain; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL,
Barcelona, Spain.
[8
]
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Department
of Pathology, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain.
[9
]
Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA),
Avenida de Pio XII, 55, 31008 Pamplona, Spain; Navarra Institute for Health Research
(IDISNA), Pamplona, Spain; Department of Oncology, Clínica Universidad de Navarra,
Pamplona, Spain.
[10
]
Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona,
Spain.
[11
]
Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA),
Avenida de Pio XII, 55, 31008 Pamplona, Spain; Navarra Institute for Health Research
(IDISNA), Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC),
Madrid, Spain; Department of Immunology and Immunotherapy, Clínica Universidad de
Navarra, Pamplona, Spain; Department of Oncology, Clínica Universidad de Navarra,
Pamplona, Spain. Electronic address: imelero@unav.es.
